Alagille syndrome due to a JAG1 point mutation

Alagille syndrome due to a JAG1 point mutation (also known as Alagille syndrome type 1 or arteriohepatic dysplasia) is a rare multisystem genetic disorder caused by point mutations in the JAG1 gene, which encodes the Jagged-1 ligand in the Notch signaling pathway. This pathway plays a critical role in embryonic development, and disruption leads to abnormalities in multiple organ systems. The condition is characterized by chronic cholestasis due to a paucity (reduced number) of intrahepatic bile ducts, which is the hallmark feature. Other major clinical features include congenital cardiac defects (most commonly peripheral pulmonary artery stenosis), butterfly vertebrae on spinal imaging, posterior embryotoxon or other ocular abnormalities, and a characteristic facial appearance with a broad forehead, deep-set eyes, pointed chin, and a straight nose giving a triangular face shape. The liver disease in Alagille syndrome can range from mild cholestasis with pruritus (itching) and jaundice in infancy to progressive liver failure requiring transplantation. Renal abnormalities, including renal dysplasia and renal tubular acidosis, may also occur. Vascular anomalies beyond the heart, including intracranial vessel abnormalities, can lead to serious complications such as stroke or intracranial bleeding. Growth retardation and failure to thrive are common in childhood. The clinical presentation is highly variable, even among affected members of the same family carrying the identical JAG1 mutation. There is currently no cure for Alagille syndrome. Treatment is primarily supportive and symptom-directed. Management of cholestasis includes ursodeoxycholic acid, fat-soluble vitamin supplementation (vitamins A, D, E, and K), nutritional support with medium-chain triglyceride-enriched formulas, and medications or surgical interventions (such as partial external biliary diversion) to manage severe pruritus. Liver transplantation is considered for patients with end-stage liver disease or intractable pruritus. The recently approved medication maralixibat, an ileal bile acid transporter inhibitor, has been approved for the treatment of cholestatic pruritus in Alagille syndrome. Cardiac defects may require surgical or catheter-based intervention. Lifelong multidisciplinary follow-up involving hepatology, cardiology, ophthalmology, nephrology, and genetics is essential.

Common questions about Alagille syndrome due to a JAG1 point mutation